



Investigating The Role of ORAI Calcium Channels On Lipopolysaccharide-Mediated Inflammatory Signaling

Turki M. Alshehri, Nasser R. Abanomi, Mohammed A. Alqinyah, Abdullah S. Alhamed, Mohammad M. Algahtani
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University

INTRODUCTION

Several studies found an association between breast cancer progression and chronic inflammation [1]. TLR4 is a major inflammatory receptor which is activated by lipopolysaccharide (LPS) [2]. Treating breast cancer cells with LPS has been shown to enhance the production of inflammatory mediators, oncogenic genes, and migration of breast cancer cells [3,4]. STIM-ORAI pathway facilitate calcium entry through specific calcium channels called ORAI channels and is thought to be essential in inflammatory signaling in immune cells [5]. Previous studies have shown that this pathway can be activated by the drug Thapsigargin and inhibited by the drug BTP2 [6,7].

OBJECTIVES

Hypothesis:

We hypothesized that using pharmacological agents that targets STIM-ORAI pathways will influence LPS-induced inflammatory signaling and the subsequent breast cancer migration.

Aims:

1- Determine the effect of the drug Thapsigargin, which activates STIM-ORAI pathway, on LPS-induced production of inflammatory genes and migration of breast cancer.

2- Investigate the effect of the drug BTP2, which is an inhibitor of STIM-ORAI pathway, on LPS-induced production of inflammatory cytokines in breast cancer cells

METHODS

Experimental design:

Breast cancer cells MDA-MB-231 (estrogen receptor-negative) were treated with:

- Control (vehicle of Serum-free media with DMSO)
- LPS alone (10 µg/ml) for 24 or 48 hours.
- LPS for 24 or 48 hours with either Thapsigargin (100nM) or BTP2 (1µM).

- Real-time PCR was used to determine gene expression of (COX-2, IL-6, and IL-8).
- ELISA was used to measure (PGE2) proteins expression.
- Cell migration was measured using an in-vitro Scratch assay.

STATISTICAL ANALYSIS:

- Each data will represent at least three independent experiments and statistical differences between different groups will be analyzed using a one-way analysis of variance (ANOVA) test followed by Tukey post hoc test. A value of $p < 0.05$ will be considered statistically significant.

RESULTS

Figure1) Thapsigargin significantly enhanced LPS-induced activation of COX-2 /PGE-2 pathway in MDA-MB-231 cells:

A:qRT-PCR analysis for mRNA of COX-2. MDA-MB-231 were treated with vehicle, LPS (10 µg/ml), LPS (10 µg/ml)+TG (100nM) for 24 hours. B: ELISA immunoassay demonstrate the level of prostaglandin E2 (PGE2) in MDA-MB-231 cell.




Figure 2) Thapsigargin significantly potentiated LPS-induced production of inflammatory genes in MDA-MB-231 cells

qRT-PCR analysis for mRNA of IL-6(C), IL-8(D).




Figure 3) LPS-induced migration of MDA-MB-231 cells is Promoted by Thapsigargin.

(E) Microscopic image of MDA-MB-231 migration after scratch (4x magnification). (F) Quantitative graph of the migrating cells (percentage).





Figure 4) BTP2 significantly inhibit LPS-induced production of inflammatory cytokines in MDA-MB-231 cells:

qRT-PCR analysis for mRNA of IL-6,(G) IL-8(H).



DISCUSSION AND CONCLUSIONS

Collectively, the data obtained from this project suggest that pharmacologically targeting STIM-ORAI pathway using Thapsigargin which is known to activate this pathway enhances LPS-induced inflammation and migration of breast cancer cells. On the other hand, the ORAI channel inhibitor BTP2 blocked LPS-induced inflammatory signaling. Therefore, our data demonstrate that STIM-ORAI pathway could be a potential novel therapeutic target in the treatment of breast cancer.

REFERENCES

